Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response

被引：12
作者：
Goode, Emily F. [1 ,2 ]
Torres, Evanthia T. Roussos [3 ]
Irshad, Sheeba [4 ,5 ]
机构：
[1] Inst Canc Res, London, England
[2] Canc Res UK CRUK Clin Fellow, London, England
[3] Univ Southern Calif, Norris Comprehens Canc Ctr, Keck Sch Med, Los Angeles, CA 90007 USA
[4] Kings Coll London, Sch Canc & Pharmaceut Sci, London, England
[5] Canc Res UK CRUK Clinician Scientist, London, England
来源：
FRONTIERS IN MOLECULAR BIOSCIENCES | 2021年 / 8卷
关键词：
lymph node; immune checkpoint inhibitor (ICI); biomarker; immune microenviroment; immune profiling; immune surveillance; CD8(+) T-CELLS; PD-1; BLOCKADE; SUPPRESSOR-CELLS; B-CELLS; TUMOR; IMMUNOTHERAPY; NIVOLUMAB; PEMBROLIZUMAB; INDUCTION; MONOTHERAPY;
D O I：
10.3389/fmolb.2021.674558
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The need for predictive biomarkers that can accurately predict patients who will respond to immune checkpoint inhibitor (ICI) immunotherapies remains a clinically unmet need. The majority of research efforts have focused on expression of immune-related markers on the tumour and its associated tumour microenvironment (TME). However, immune response to tumour neoantigens starts at the regional lymph nodes, where antigen presentation takes place and is regulated by multiple cell types and mechanisms. Knowledge of the immunological responses in bystander lymphoid organs following ICI therapies and their association with changes in the TME, could prove to be a valuable component in understanding the treatment response to these agents. Here, we review the emerging data on assessment of immunological responses within regional lymph nodes as predictive biomarkers for immunotherapies.
引用
收藏
页数：9
相关论文
共 54 条
  • [21] Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent
    Kamphorst, Alice O.
    Wieland, Andreas
    Nasti, Tahseen
    Yang, Shu
    Zhang, Ruan
    Barber, Daniel L.
    Konieczny, Bogumila T.
    Daugherty, Candace Z.
    Koenig, Lydia
    Yu, Ke
    Sica, Gabriel L.
    Sharpe, Arlene H.
    Freeman, Gordon J.
    Blazar, Bruce R.
    Turka, Laurence A.
    Owonikoko, Taofeek K.
    Pillai, Rathi N.
    Ramalingam, Suresh S.
    Araki, Koichi
    Ahmed, Rafi
    [J]. SCIENCE, 2017, 355 (6332) : 1423 - 1427
  • [22] Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer
    Kohrt, HE
    Nouri, N
    Nowels, K
    Johnson, D
    Holmes, S
    Lee, PP
    [J]. PLOS MEDICINE, 2005, 2 (09) : 904 - 919
  • [23] Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients
    Kotsakis, Athanasios
    Koinis, Filippos
    Katsarou, Afroditi
    Gioulbasani, Marianthi
    Aggouraki, Despoina
    Kentepozidis, Nikolaos
    Georgoulias, Vassilis
    Vetsika, Eleni-Kyriaki
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [24] PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
    Le, D. T.
    Uram, J. N.
    Wang, H.
    Bartlett, B. R.
    Kemberling, H.
    Eyring, A. D.
    Skora, A. D.
    Luber, B. S.
    Azad, N. S.
    Laheru, D.
    Biedrzycki, B.
    Donehower, R. C.
    Zaheer, A.
    Fisher, G. A.
    Crocenzi, T. S.
    Lee, J. J.
    Duffy, S. M.
    Goldberg, R. M.
    de la Chapelle, A.
    Koshiji, M.
    Bhaijee, F.
    Huebner, T.
    Hruban, R. H.
    Wood, L. D.
    Cuka, N.
    Pardoll, D. M.
    Papadopoulos, N.
    Kinzler, K. W.
    Zhou, S.
    Cornish, T. C.
    Taube, J. M.
    Anders, R. A.
    Eshleman, J. R.
    Vogelstein, B.
    Diaz, L. A., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) : 2509 - 2520
  • [25] Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
    Liu, Jing
    Blake, Stephen J.
    Yong, Michelle C. R.
    Harjunpaa, Heidi
    Ngiow, Shin Foong
    Takeda, Kazuyoshi
    Young, Arabella
    O'Donnell, Jake S.
    Allen, Stacey
    Smyth, Mark J.
    Teng, Michele W. L.
    [J]. CANCER DISCOVERY, 2016, 6 (12) : 1382 - 1399
  • [26] Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma
    Maibach, Fabienne
    Sadozai, Hassan
    Seyed Jafari, S. Morteza
    Hunger, Robert E.
    Schenk, Mirjam
    [J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [27] Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy
    Mangan, Brendan L.
    McAlister, Renee K.
    Balko, Justin M.
    Johnson, Douglas B.
    Moslehi, Javid J.
    Gibson, Andrew
    Phillips, Elizabeth J.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (09) : 1778 - 1789
  • [28] Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
    Marvel, Douglas
    Gabrilovich, Dmitry I.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (09) : 3356 - 3364
  • [29] Marzo AL, 1999, J IMMUNOL, V162, P5838
  • [30] Biomarkers of immune checkpoint inhibitor efficacy in cancer
    Meyers, D. E.
    Banerji, S.
    [J]. CURRENT ONCOLOGY, 2020, 27 : S106 - S114
123456